)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
InMed Pharmaceuticals
InMed Pharmaceuticals (INM) investor relations material
InMed Pharmaceuticals Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary11 Feb, 2026
Executive summary
Focus on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors and rare cannabinoid manufacturing for health and wellness sectors.
Pipeline includes INM-901 for Alzheimer's, INM-089 for dry AMD, and INM-755 for EB, with recent progress in preclinical and clinical studies.
Advanced INM-901 for Alzheimer's, completing key preclinical pharmacokinetic studies with robust bioavailability and no adverse effects, supporting progression to human trials.
INM-089 for dry AMD showed significant functional and pathological improvements in preclinical models, with successful high-dose delivery.
Subsidiary BayMedica faces regulatory risk from new U.S. legislation that could prohibit certain cannabinoid products.
Financial highlights
Revenue for the quarter was $820,188, down 26% year-over-year; six-month revenue was $1,940,309, down 18%.
BayMedica's commercial revenue was $0.8 million for Q2 FY2026, down 26% year-over-year due to anticipated legislative changes.
Net loss for the quarter was $2,028,223, compared to $2,575,024 in the prior year; six-month net loss was $3,755,122, improved from $4,252,892.
Net loss for the quarter was $3.8 million, compared to $4.3 million in the prior year period.
Cash, cash equivalents, and short-term investments totaled $7.0 million as of December 31, 2025, down from $11.1 million at June 30, 2025.
Outlook and guidance
Cash reserves expected to fund operations into Q4 2026, contingent on BayMedica revenue and expense levels.
Substantial doubt exists about the ability to continue as a going concern without additional capital.
R&D expenses are projected to increase as preclinical and IND-enabling studies for INM-901 progress.
Preparing for pre-IND meetings with the FDA for both INM-901 and INM-089 in 2026.
Ongoing evaluation of BayMedica's business model in response to potential regulatory changes.
BayMedica's contingency for H.R. 5371 impact?
INM-901/089 IND submission timeline?
What R&D milestones drive increased spending?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next InMed Pharmaceuticals earnings date
Q3 202612 May, 2026
InMed Pharmaceuticals
Next InMed Pharmaceuticals earnings date
Q3 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
InMed Pharmaceuticals Inc is a Canadian biotechnology company specializing in the research and development of rare cannabinoids. The company focuses on creating pharmaceutical and consumer health products derived from cannabinoid compounds using biosynthesis and chemical synthesis technologies. Its operations span proprietary drug development and manufacturing services. InMed Pharmaceuticals Inc is headquartered in Vancouver, Canada, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage